<DOC>
	<DOCNO>NCT02838069</DOCNO>
	<brief_summary>ASCs administer via intra-articular use knee joint affect OA expect exert therapeutic effect . The objective clinical trial generate efficacy tolerability profile single injection 2 dosage autologous ASCs versus standard care ( placebo ) , administer locally knee joint affect OA vitro cell expansion . The potential ASC lead disease-modifying therapeutic option treatment chronic debilitate disease assess MRI 1 2 year . This phase IIb , multi-centre , prospective , randomize , double-blind study , compare culture-expanded autologous ASC placebo .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells Patients With Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Symptomatic mild moderate osteoarthritis ( OA ) index knee define American college Rheumatology ( ACR ) Must meet pain criterion time screening/baseline visit since least half day previous month NSAID washout least 2 day screening/baseline Previous treatment act cartilage bone metabolism Received intraarticular injection corticosteroid , platelet rich plasma hyaluronic acid within previous 6 month , Significant trauma surgery index knee within last year arthroscopy index knee within 12 month screen . KellgrenLawrence Grade 1 4 index knee incidence . Osteoarthritis cause significant pain joint identify knee , i.e. , pain hip , contralateral knee ( â‰¥ 20 mm pain ) confirm separate VAS baseline painful joint concerned History joint replacement knee hip within previous 12 month</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>